Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.

Area of Science:

• Oncology
• Epidemiology
• Cancer Research

Background:

• Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma.
• The risk of developing a second primary malignancy (SPM) after an MCL diagnosis is not well-established.
• Population-based studies are crucial for understanding long-term cancer risks.

Purpose of the Study:

• To investigate the incidence and risk of SPMs in adult patients diagnosed with MCL.
• To identify specific types of SPMs that occur at higher rates in MCL survivors.
• To provide data that can inform follow-up care and screening protocols for MCL patients.

Main Methods:

• Utilized the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) 13 database.
• Included adult patients (≥18 years) diagnosed with MCL between January 1992 and December 2011.
• Employed standardized incidence ratio (SIR) methods to compare SPM rates in MCL patients to the general population.

Main Results:

• A total of 3,149 MCL patients were analyzed, with 261 (8.29%) developing 287 SPMs.
• An overall increased risk of SPM was observed (O/E ratio = 1.32, p<0.001).
• Significant excess risks were found for specific cancers including skin (excluding basal/squamous), thyroid, acute myeloid leukemia, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.

Conclusions:

• Mantle cell lymphoma survivors have a statistically significant higher risk of developing second primary malignancies.
• Certain SPMs, such as skin, thyroid, and hematologic malignancies, warrant particular attention.
• Cancer-specific screening during follow-up may benefit patients treated for MCL.